Pharma Giants Face China Trial Scrutiny | Durham News

Durham News Today | 2 Min News | The Daily News Now! · Jul 2, 2026 · 1m

Five major U.S. pharma giants — Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb — are under fire from the House Select Committee on China, facing demands to explain their clinical trial operations in China, especially in Xinjiang and military-linked sites, with a July 17 deadline. The probe raises alarms over data security, ethical risks, and potential IP theft as China’s faster, cheaper trials threaten U.S. biotech dominance. Stock dips for Eli Lilly and AbbVie signal investor concern, while a new bill seeks to review U.S.-China biotech deals — and the pressure is only escalating…